Trial reportClinical pharmacokinetics1989
Clinical pharmacokinetics of ceftriaxone.
Trial report in Clinical pharmacokinetics, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.Journal of clinical pharmacology · 2014Trial
- Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty.Antimicrobial agents and chemotherapy · 1997Trial
- Reversal of Borrelia burgdorferi associated dilated cardiomyopathy by antibiotic treatment?Cardiovascular drugs and therapy · 1996Trial
- Article
- Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage.International journal of molecular sciences · 2022Article
- Pharmacodynamics of Ceftriaxone, Ertapenem, Fosfomycin and Gentamicin inAntibiotics (Basel, Switzerland) · 2022Article
- Ceftriaxone therapy attenuates brain trauma in rats by affecting glutamate transporters and neuroinflammation and not by its antibacterial effects.BMC neuroscience · 2021Article
- Serious Neurological Adverse Events of Ceftriaxone.Antibiotics (Basel, Switzerland) · 2021Article
- "Effect of Subinhibitory Concentrations of Some Antibiotics and Low Doses of Gamma Radiation on the Cytotoxicity and Expression of Colibactin by an Uropathogenic Escherichia coli isolate".Current microbiology · 2021Article
- Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?Antimicrobial agents and chemotherapy · 2020Article
- Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia.European journal of clinical pharmacology · 2020Article
- Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan.PLoS neglected tropical diseases · 2020Article
- The efficacy of ampicillin compared with ceftriaxone on preventing cesarean surgical site infections: an observational prospective cohort study.Antimicrobial resistance and infection control · 2018Article
- Assessment of oritavancin serum protein binding across species.Antimicrobial agents and chemotherapy · 2010Article
- Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis.Antimicrobial agents and chemotherapy · 2009Article
- Effect of protein binding on the pharmacological activity of highly bound antibiotics.Antimicrobial agents and chemotherapy · 2008Article
- Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2004Review
- Protein binding predictions in infants.AAPS pharmSci · 2002Article
- Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.Drugs · 2002Review
- Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.Clinical pharmacokinetics · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftriaxone is a third-generation cephalosporin that exhibits saturable plasma protein binding, which influences its pharmacokinetic parameters depending on the dose. Systemic clearance and volume of distribution of total drug show dependence on both concentration and time, whereas for unbound drug these parameters remain constant. The decrease in renal or non-renal clearance with age or in the presence of disease states is often compensated by the concurrent increase in free fraction, resulting in no apparent changes in half-life and no need for dose adjustment. Because of its unusually long plasma half-life, the availability of intramuscular administration and its high intrinsic activity against many organisms, ceftriaxone has become a popular agent in once-daily therapy of infections in paediatric patients, gonococcal infections and outpatient management of pneumonia and osteomyelitis.
Indexed as
Identifiers
2686882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.